Pharmacological Therapy for Ischemic Stroke Patients Accordance to Clinical Practice Guidelines

Stroke ranks as the second most common cause of mortality and the third most significant cause of disability globally. The frequency of stroke remains elevated in low- and middle-income countries, affecting 70% of the population. Additionally, stroke-related deaths and disability-adjusted life years might reach as high as 87%. This study aims to evaluate the suitability of a pharmacological treatment approach for stroke patients in Malaysia, specifically in a public hospital setting. The evaluation will be based on the Clinical Practice Guidelines (CPG) 2012. A four-year retrospective, cross-sectional study was undertaken using medical records conducted among (n=682) hospitalized patients at Sungai Buloh Hospital; only (n=126) conforms with inclusion criteria and confirmed ischemic stroke diagnoses. Data was gathered utilizing a self-created data-collecting form that included demographic information, comorbidity, and pharmacological treatment. The mean age of the reported cases was 66.66 years, with the majority (58%) males and only (42%) females. The compliance to the Clinical Practice Guideline Malaysia 2012 for ischemic stroke inpatient setting in a public hospital is (>72%) (p=0.001). A significant proportion of patients had pharmacological therapeutic management in adherence to stroke recommendations, which is considered a critical factor in reducing stroke-related disability and mortality.